Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Drug

Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III

Fineline Cube Sep 9, 2026
Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Fineline Cube Sep 9, 2026
Company Deals

Adicon Holdings and Guardant Health Partner on Genomic Profiling in China

Fineline Cube Jul 7, 2022

China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...

Company Deals

BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development

Fineline Cube Jul 7, 2022

China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with...

Company Deals

PackGene and SineuGene Partner on ALS Gene Therapy Research

Fineline Cube Jul 7, 2022

China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus...

Policy / Regulatory

China Establishes Leadership Group to Combat Drug-Related Crimes

Fineline Cube Jul 7, 2022

China’s State Council executive body released a notification regarding the establishment of a leadership group...

Company Deals Digital

Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push

Fineline Cube Jul 7, 2022

Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study

Fineline Cube Jul 7, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Company Drug

Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study

Fineline Cube Jul 6, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Drug

GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome

Fineline Cube Jul 6, 2022

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from...

Company Drug

Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study

Fineline Cube Jul 6, 2022

China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient...

Company Deals

ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion

Fineline Cube Jul 6, 2022

Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a...

Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review

Fineline Cube Jul 6, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...

Company Deals

Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development

Fineline Cube Jul 6, 2022

China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...

Drug

Ascletis Pharma Files IND Application for ASC10 with US FDA

Fineline Cube Jul 6, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...

Company Drug

MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jul 6, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment

Fineline Cube Jul 6, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...

Company Deals

Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion

Fineline Cube Jul 6, 2022

China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...

Company Drug

Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA

Fineline Cube Jul 6, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...

Company Digital

Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss

Fineline Cube Jul 6, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...

Company Policy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Fineline Cube Jul 6, 2022

Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...

Policy / Regulatory R&D

CDE Releases 60th Batch of Chemical Generic Reference Preparations

Fineline Cube Jul 6, 2022

The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...

Posts pagination

1 … 705 706 707 … 718

Recent updates

  • Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III
  • CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops
  • Gilead Opens Foster City Research Center for Oncology and Inflammation
  • Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data
  • China Launches Five-Year Plan to Expand High-Quality Eye Health Services
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III

Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Company Drug

Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.